Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel E Furst

Showing results (51-60 of 477) with videos related to

Pageof 48
Sort By:
Open Access Rheumatology : Research and Reviews|August 9, 2012
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretationShatara V Townes, Daniel E Furst, Anuradha Thenkondar
The Korean Journal of Internal Medicine|March 3, 2010
Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritisSteven S Storage, Harsh Agrawal, Daniel E Furst
The Journal of Rheumatology|October 16, 2004
Mechanisms of action of tumor necrosis factor antagonist and granulomatous infectionsDavid Beenhouwer, Robert Wallis, Michael Broder, et al.
The New England Journal of Medicine|March 15, 2018
Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Daniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 28, 2017
A Case Series on Patients on Tofacitinib in Combination With a BiologicNashla S Barroso, Elizabeth Z Miller, Daniel E Furst
Current Rheumatology Reports|March 9, 2016
Infection and Lupus: Which Causes Which?Sarah Doaty, Harsh Agrawal, Erin Bauer, et al.
Clinics in Dermatology|September 13, 2006
Systemic and localized sclerodermaLorinda Chung, Jan Lin, Daniel E Furst, et al.
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for designing trials in systemic sclerosis patients with arthritic involvementPhilip Clements, Yannick Allanore, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|August 4, 2006
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionDaniel E Furst, Robert Wallis, Michael Broder, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary InvolvementKeith M Sullivan, Ankoor Shah, Stefanie Sarantopoulos, et al.
Pageof 48

Showing results (51-60 of 477) with videos related to

Sort By:
Pageof 48
Open Access Rheumatology : Research and Reviews|August 9, 2012
The impact of tocilizumab on physical function and quality of life in patients with rheumatoid arthritis: a systematic literature review and interpretationShatara V Townes, Daniel E Furst, Anuradha Thenkondar
The Korean Journal of Internal Medicine|March 3, 2010
Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritisSteven S Storage, Harsh Agrawal, Daniel E Furst
The Journal of Rheumatology|October 16, 2004
Mechanisms of action of tumor necrosis factor antagonist and granulomatous infectionsDavid Beenhouwer, Robert Wallis, Michael Broder, et al.
The New England Journal of Medicine|March 15, 2018
Autologous Stem-Cell Transplantation for Severe SclerodermaKeith M Sullivan, Ellen A Goldmuntz, Daniel E Furst
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|December 28, 2017
A Case Series on Patients on Tofacitinib in Combination With a BiologicNashla S Barroso, Elizabeth Z Miller, Daniel E Furst
Current Rheumatology Reports|March 9, 2016
Infection and Lupus: Which Causes Which?Sarah Doaty, Harsh Agrawal, Erin Bauer, et al.
Clinics in Dermatology|September 13, 2006
Systemic and localized sclerodermaLorinda Chung, Jan Lin, Daniel E Furst, et al.
Rheumatology (Oxford, England)|October 10, 2017
Points to consider for designing trials in systemic sclerosis patients with arthritic involvementPhilip Clements, Yannick Allanore, Daniel E Furst, et al.
Seminars in Arthritis and Rheumatism|August 4, 2006
Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infectionDaniel E Furst, Robert Wallis, Michael Broder, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 24, 2016
Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary InvolvementKeith M Sullivan, Ankoor Shah, Stefanie Sarantopoulos, et al.
Pageof 48